rss
Heart doi:10.1136/hrt.2006.095208

Effects of Long-term Treatment with Carvedilol on Myocardial Blood Flow in Idiopathic Dilated Cardiomyopathy

  1. Danilo Neglia (dneglia{at}ifc.cnr.it)
  1. CNR Institute of Clinical Physiology, Italy
    1. Renata De Maria (ifcnig{at}tin.it)
    1. CNR Institute of Clinical Physiology, Italy
      1. Stefano Masi (stefano.masi{at}ifc.cnr.it)
      1. University of Pisa, Italy
        1. Michela Gallopin
        1. Ospedale di Prato, Italy
          1. Patrizia Pisani (patty{at}ifc.cnr.it)
          1. CNR Institute of Clinical Physiology, Italy
            1. Silvia Pardini (spardini{at}ifc.cnr.it)
            1. CNR Institute of Clinical Physiology, Italy
              1. Antonello Gavazzi
              1. Ospedali Riuniti di Bergamo, Italy
                1. Antonio L'Abbate (segrlabb{at}ifc.cnr.it)
                1. Scuola Superiore Sant Anna, Pisa, Italy
                  1. Oberdan Parodi (oberpar{at}tin.it)
                  1. CNR Institute of Clinical Physiology, Italy
                    • Published Online First 19 January 2007

                    Abstract

                    Objective To assess whether chronic treatment with carvedilol is able to increase myocardial blood flow (MBF) and MBF reserve in idiopathic dilated cardiomyopathy (IDC).

                    Study Design In a double-blind, placebo-controlled trial, 16 consecutive IDC patients were randomized to treatment with carvedilol up to 25 mg b.i.d (8 pts, 7 males, mean age 60iÓ9 years, mean LVEF 30iÓ%) or placebo (8 pts, 6 males, mean age 62iÓ9 years, mean LVEF 28iÓ6%, ns vs carvedilol group). Before and six months after treatment, regional MBF was measured at rest and after i.v. dipyridamole (0.56 mg/Kg in 4') by positron emission tomography and 13N-Ammonia. Exercise capacity was assessed as time duration in a maximal bicycle exercise stress test.

                    Results Carvedilol induced a significant decrease in resting and maximal exercise heart rate and increase in exercise capacity. Absolute MBF values did not significantly change after carvedilol or placebo either at rest and during dipyridamole. In patients treated with carvedilol, dipyridamole MBF tended to improve after treatment and MBF reserve significantly increased (from 1.67iÓ0.63 to 2.58iÓ1.04, p<0.001) while it remained unchanged in the placebo group (from 1.80iÓ0.84 to 1.77iÓ0.60, ns). Stress-induced regional perfusion defects decreased after carvedilol (from 38% to 15%).

                    Conclusions Long-term treatment with carvedilol is able to significantly increase MBF reserve and to reduce the occurrence of stress induced perfusion defects suggesting a favourable effect of the drug on coronary microvascular function in patients with IDC.

                    This Article

                    1. Abstract
                    2. PDF
                    3. All versions of this article:
                      1. hrt.2006.095208v1
                      2. 93/7/808most recent

                    Responses

                    1. Submit a response
                    2. No responses published

                    Latest from Education in Heart

                    Latest from Education in Heart

                    Register for free content

                    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

                    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.